TransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low - Here's Why

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares hit a new 52-week low during trading on Thursday . The company traded as low as $57.90 and last traded at $58.02, with a volume of 2203853 shares trading hands. The stock had previously closed at $60.44.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research analyst reports. Baird R W upgraded shares of TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, December 11th. Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Price Performance

The company has a market cap of $1.95 billion, a price-to-earnings ratio of 61.72 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a fifty day moving average price of $72.63 and a two-hundred day moving average price of $119.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares of the company's stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new position in TransMedics Group in the 3rd quarter valued at $2,560,000. Charles Schwab Investment Management Inc. raised its holdings in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock valued at $42,656,000 after buying an additional 6,634 shares during the last quarter. Zacks Investment Management bought a new position in shares of TransMedics Group in the third quarter valued at about $1,607,000. Vaughan Nelson Investment Management L.P. lifted its position in TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company's stock worth $51,654,000 after buying an additional 64,360 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in TransMedics Group by 665.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company's stock worth $11,716,000 after acquiring an additional 64,872 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.